Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 2:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 2,114 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Metastatic Breast Carcinoma Clear all
Completed Phase 2 Interventional Results available

Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer

NCT00654836
View directory record Official record
Conditions
Breast Cancer
Interventions
bevacizumab, Carboplatin, ABI-007
Biological · Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
6
States / cities
Downers Grove, Illinois • Geneva, Illinois • Maywood, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2017 · Synced Oct 15, 2026, 2:05 AM EDT
Completed Phase 1 Interventional

Study of NK012 and Carboplatin in Solid Tumors With Dose Expansion in Triple Negative Breast Cancer

NCT01238952
View directory record Official record
Conditions
Advanced Solid Tumors, Metastatic Triple Negative Breast Cancer
Interventions
NK012 and carboplatin
Drug
Lead sponsor
Nippon Kayaku Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 13, 2014 · Synced Oct 15, 2026, 2:05 AM EDT
Completed Phase 2 Interventional Results available

Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis

NCT05185947
View directory record Official record
Conditions
Gynecologic Cancer, Gynecologic Neoplasms, Peritoneal Carcinomatosis, Peritoneal Neoplasms, Ovarian Cancer, Ovarian Neoplasms, Colorectal Cancer, Colorectal Neoplasms, Appendiceal Cancer, Appendiceal Neoplasms, Cholangiocarcinoma, Breast Cancer
Interventions
Paclitaxel, Nilotinib, ECG, CT Scan CAP, Laparoscopy, Peritoneal biopsies + ascites washings
Drug · Diagnostic Test · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 15, 2026, 2:05 AM EDT
Terminated Phase 2 Interventional Results available

A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma

NCT03207867
View directory record Official record
Conditions
NSCLC, Non Small Cell Lung Cancer, RCC, Renal Cell Cancer, Pancreatic Cancer, Urothelial Cancer, Head and Neck Cancer, DLBCL, Diffused Large B Cell Lymphoma, MSS, Microsatellite Stable Colon Cancer, TNBC, Triple Negative Breast Cancer, Melanoma, mCRPC, Metastatic Castration Resistant Prostate Cancer
Interventions
NIR178, PDR001
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
5
States / cities
Santa Monica, California • Tampa, Florida • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 15, 2026, 2:05 AM EDT
Completed Phase 1 Interventional

Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors

NCT01640665
View directory record Official record
Conditions
Metastatic Breast Cancer, Gastrointestinal Tumors
Interventions
Sorafenib, Capecitabine
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 16, 2016 · Synced Oct 15, 2026, 2:05 AM EDT
Recruiting Not applicable Interventional

Exercise in Metastatic Breast Cancer: EMBody

NCT05468034
View directory record Official record
Conditions
Breast Cancer, Indolent Metastatic Breast Cancer
Interventions
Exercise Intervention
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
6
States / cities
New Haven, Connecticut • Avon, Indiana • Carmel, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 15, 2026, 2:05 AM EDT
Recruiting Phase 2 Interventional

Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling

NCT04965064
View directory record Official record
Conditions
Breast Cancer
Interventions
Capecitabine and Neratinib.
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 15, 2026, 2:05 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Trastuzumab and Erlotinib as First-Line Therapy in Treating Women With Metastatic Breast Cancer Associated With HER2/Neu Overexpression

NCT00033514
View directory record Official record
Conditions
Breast Cancer
Interventions
trastuzumab, erlotinib hydrochloride
Biological · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 15, 2026, 2:05 AM EDT
Completed Phase 2 Interventional

Study in Women With Metastatic Breast Cancer Whose Cancer Has Gotten Worse After Anthracycline and Taxane Therapy

NCT00067314
View directory record Official record
Conditions
Breast Neoplasms, Neoplasm Metastasis
Interventions
Edotecarin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
7
States / cities
Manhasset, New York • New York, New York • Cleveland, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2012 · Synced Oct 15, 2026, 2:05 AM EDT
Completed Phase 1 Interventional

Study of the Safety and Pharmacology of GDC-0980 in Combination With Paclitaxel With or Without Bevacizumab in Patients With Locally Recurrent or Metastatic Breast Cancer

NCT01254526
View directory record Official record
Conditions
Breast Cancer
Interventions
GDC-0980, bevacizumab, paclitaxel
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
Boston, Massachusetts • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 15, 2026, 2:05 AM EDT
Active, not recruiting Phase 2 Interventional

Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib

NCT05323955
View directory record Official record
Conditions
Brain Metastases, Human Epidermal Growth Factor 2 Positive Carcinoma of Breast, Advanced Breast Cancer
Interventions
Trastuzumab, Trastuzumab Emtansine (T-DM1), Pertuzumab, Tucatinib
Drug
Lead sponsor
Carey Anders, M.D.
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
8
States / cities
San Francisco, California • Boston, Massachusetts • Ann Arbor, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 15, 2026, 2:05 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer

NCT02066532
View directory record Official record
Conditions
Metastatic Breast Cancer, Breast Carcinoma, HER-2 Positive Breast Cancer
Interventions
Ruxolitinib, Trastuzumab
Drug
Lead sponsor
Dawn L. Hershman
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
4
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 24, 2023 · Synced Oct 15, 2026, 2:05 AM EDT
Completed Phase 2 Interventional Results available

Study of Concurrent Paclitaxel and Radiation: Correlation of Tumor Profiles With Pathologic Response

NCT02280252
View directory record Official record
Conditions
Breast Cancer
Interventions
Paclitaxel, Radiation therapy
Drug · Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Female only
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 15, 2026, 2:05 AM EDT
Terminated Phase 2 Interventional Results available

A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study)

NCT02034916
View directory record Official record
Conditions
Breast Neoplasms, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation
Interventions
talazoparib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
37
States / cities
Greenbrae, California • Los Angeles, California • Palo Alto, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2019 · Synced Oct 15, 2026, 2:05 AM EDT
Terminated Phase 2 Interventional Results available

Ph II Letrozole + OSI-774 (Tarceva) in Post-menopausal, w/ ER and/or PR-positive Met Breast Cancer.

NCT00611715
View directory record Official record
Conditions
Breast Cancer
Interventions
erlotinib hydrochloride, letrozole, fluorescence in situ hybridization, immunohistochemistry staining method, laboratory biomarker analysis
Drug · Genetic · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
9
States / cities
Macon, Georgia • Hopkinsville, Kentucky • Paducah, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2012 · Synced Oct 15, 2026, 2:05 AM EDT
Active, not recruiting Phase 2 Interventional

ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)

NCT04829604
View directory record Official record
Conditions
HER2 Positive Metastatic Breast Cancer
Interventions
ARX788
Drug
Lead sponsor
Ambrx, Inc.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
25
States / cities
Los Angeles, California • Newport Beach, California • San Francisco, California + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 15, 2026, 2:05 AM EDT
Terminated No phase listed Observational Results available

HR+/ HER2- Advanced/ Metastatic Breast Cancer Real World Treatment Patterns and Outcomes

NCT04396626
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
975 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Oct 15, 2026, 2:05 AM EDT
Completed Phase 2 Interventional Results available

A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors

NCT05001347
View directory record Official record
Conditions
Ovarian Cancer, Head and Neck Cancer, Non Small Cell Lung Cancer, Gastrointestinal Cancer, Triple Negative Breast Cancer, Ovarian Carcinoma
Interventions
TJ004309
Drug
Lead sponsor
I-Mab Biopharma US Limited
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
15
States / cities
Tucson, Arizona • Whittier, California • Newark, Delaware + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 15, 2026, 2:05 AM EDT
Completed Phase 2 Interventional Results available

Estradiol Suppression for the Treatment of Metastatic Breast Cancer in Premenopausal Women

NCT00186121
View directory record Official record
Conditions
Breast Cancer
Interventions
Anastrozole (Arimidex), Goserelin (Zoladex)
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2013
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Oct 15, 2026, 2:05 AM EDT
Completed Early Phase 1 Interventional

Oxaliplatin in Treating Patients With Metastatic Breast Cancer

NCT02077998
View directory record Official record
Conditions
Stage IV Breast Cancer
Interventions
carbon C 14 oxaliplatin, oxaliplatin, laboratory biomarker analysis
Radiation · Drug · Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 9, 2018 · Synced Oct 15, 2026, 2:05 AM EDT
Completed Phase 2 Interventional

Enzastaurin For Breast Cancer Patients Who Previously Received an Anthracycline and a Taxane Chemotherapy

NCT00386087
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Enzastaurin Hydrochloride
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
4
States / cities
Newark, Delaware • Indianapolis, Indiana • South Bend, Indiana + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2008 · Synced Oct 15, 2026, 2:05 AM EDT
Terminated Phase 1 Interventional

A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors

NCT06264921
View directory record Official record
Conditions
Solid Tumor, Solid Tumor, Adult, Advanced Solid Tumor, Metastatic Tumor, Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Metastatic Ovarian Carcinoma, Endometrial Cancer, Endometrial Neoplasms, Endometrial Diseases, Metastatic Endometrial Cancer, Metastatic Endometrial Carcinoma, Advanced Endometrial Carcinoma, Advanced Ovarian Carcinoma, Gastric Cancer, Advanced Gastric Carcinoma, Metastatic Gastric Cancer, Metastatic Gastric Carcinoma, Small-cell Lung Cancer, Small Cell Lung Carcinoma, Triple Negative Breast Cancer, Triple Negative Breast Neoplasms, Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Carcinoma, CCNE1 Amplification, Hormone Receptor Negative Breast Carcinoma, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Progesterone-receptor-positive Breast Cancer
Interventions
NKT3447
Drug
Lead sponsor
NiKang Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
8
States / cities
San Francisco, California • Denver, Colorado • Celebration, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 15, 2026, 2:05 AM EDT
Completed No phase listed Observational

Enhancing Shared Decision-Making in Metastatic Breast Cancer (Qualitative Study)

NCT03248258
View directory record Official record
Conditions
Decision Making ,Shared, De-escalation
Interventions
Qualitative Interview or Focus group discussions
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 15, 2026, 2:05 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer

NCT01216176
View directory record Official record
Conditions
Breast Cancer
Interventions
Anastrozole, AZD0530 (saracatinib), Placebo
Drug
Lead sponsor
Joyce Marie Slingerland, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
2
States / cities
Palo Alto, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Oct 15, 2026, 2:05 AM EDT